Referencias:

• Ouellet, M., Mercier, S., Pelletier, I., Bounou, S., Roy, J., Hirabayashi, J., Galectin-1 acts as a soluble host factor that promotes HIV-1 infectivity through stabilization of virus attachment to host cells (2005) J Immunol, 174, pp. 4120-4126
• Mercier, S., St-Pierre, C., Pelletier, I., Ouellet, M., Tremblay, M.J., Sato, S., Galectin-1 promotes HIV-1 infectivity in macrophages through stabilization of viral adsorption (2008) Virology, 371, pp. 121-129
• St-Pierre, C., Manya, H., Ouellet, M., Clark, G.F., Endo, T., Tremblay, M.J., Sato, S., Host-soluble galectin-1 promotes HIV-1 replication through a direct interaction with glycans of viral gp120 and host CD4 (2011) J Virol, 85, pp. 11742-11751
• Juszczynski, P., Ouyang, J., Monti, S., Rodig, S.J., Takeyama, K., Abramson, J., The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma (2007) Proc Natl Acad Sci USA, 104, pp. 13134-13139
• Cedeno-Laurent, F., Watanabe, R., Teague, J.E., Kupper, T.S., Clark, R.A., Dimitroff, C.J., Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma (2012) Blood, 119, pp. 3534-3538
• Croci, D.O., Salatino, M., Rubinstein, N., Cerliani, J.P., Cavallin, L.E., Leung, H.J., Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma (2012) J Exp Med, 209, pp. 1985-2000
• Kamper, P., Ludvigsen, M., Bendix, K., Hamilton-Dutoit, S., Rabinovich, G.A., Moller, M.B., Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma (2011) Blood, 117, pp. 6638-6649
• Ouyang, J., Plütschow, A., Pogge Von Strandmann, E., Reiners, K.S., Ponader, S., Rabinovich, G.A., Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma (2013) Blood, 121, pp. 3431-3433
• Rubinstein, N., Alvarez, M., Zwirner, N.W., Toscano, M.A., Ilarregui, J.M., Bravo, A., Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege (2004) Cancer Cell, 5, pp. 241-251
• Ouyang, J., Juszczynski, P., Rodig, S.J., Green, M.R., O'Donnell, E., Currie, T., Viral induction and targeted inhibition of galectin-1 in EBVR posttransplant lymphoproliferative disorders (2011) Blood, 117, pp. 4315-4322
• Dalotto-Moreno, T., Croci, D.O., Cerliani, J.P., Martinez-Allo, V.C., Dergan-Dylon, S., Méndez-Huergo, S.P., Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease (2013) Cancer Res, 73, pp. 1107-1117
• Laderach, D.J., Gentilini, L.D., Giribaldi, L., Delgado, V.C., Nugnes, L., Croci, D.O., A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease (2013) Cancer Res, 73, pp. 86-96
• Croci, D.O., Cerliani, J.P., Dalotto-Moreno, T., Méndez-Huergo, S.P., Mascanfroni, I.D., Dergan-Dylon, S., Glycosylationdependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors (2014) Cell, 156, pp. 744-758
• Vase, M., Ludvigsen, M., Bendix, K., Hamilton-Dutoit, S., Mller, M.B., Pedersen, C., Proteomic profiling of pretreatment serum from HIV-infected patients identifies candidate markers predictive of lymphoma development (2016) AIDS, 30, pp. 1889-1898
• Petruskevicius, I., Ludvigsen, M., Hjortebjerg, R., Sørensen, B.S., Kamper, P., Vase, M., Clinical relevance of galectin-1 in hematologic malignancies treated with non-myeloablative hemopoietic stem cell transplantation (2016) Bone Marrow Transplant, 51, pp. 1387-1390
• Rabkin, C.S., Engels, E.A., Landgren, O., Schuurman, R., Camargo, M.C., Pfeiffer, R., Goedert, J.J., Circulating cytokine levels, Epstein-Barr viremia and risk of acquired immunodeficiency syndromerelated non-Hodgkin lymphoma (2011) Am J Hematol, 86, pp. 875-878
• Breen, E.C., Hussain, S.K., Magpantay, L., Jacobson, L.P., Detels, R., Rabkin, C.S., B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma (2011) Cancer Epidemiol Biomarkers Prev, 20, pp. 1303-1314
• Hussain, S.K., Hessol, N.A., Levine, A.M., Breen, E.C., Anastos, K., Cohen, M., Serum biomarkers of immune activation and subsequent risk of non-Hodgkin B-cell lymphoma among HIV-infected women (2013) Cancer Epidemiol Biomark Prev, 22, pp. 2084-2093
• Toscano, M.A., Campagna, L., Molinero, L.L., Cerliani, J.P., Croci, D.O., Ilarregui, J.M., Nuclear factor (NF)-kB controls expression of the immunoregulatory glycan-binding protein galectin-1 (2011) Mol Immunol, 48, pp. 1940-1949
• Rodig, S.J., Ouyang, J., Juszczynski, P., Currie, T., Law, K., Neuberg, D.S., AP1-dependent galectin-1 expression delineates classical Hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features (2008) Clin Cancer Res, 14, pp. 3338-3344
• Liapis, K., Clear, A., Owen, A., Coutinho, R., Greaves, P., Lee, A.M., The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies (2013) Blood, 122, pp. 424-433
• Chao, C., Silverberg, M.J., Xu, L., Chen, L.H., Castor, B., Martnez-Maza, O., A comparative study of molecular characteristics of diffuse large B-cell lymphoma from patients with and without human immunodeficiency virus infection (2015) Clin Cancer Res, 21, pp. 1429-1437
• Barrionuevo, P., Beigier-Bompadre, M., Ilarregui, J.M., Toscano, M.A., Bianco, G.A., Isturiz, M.A., Rabinovich, G.A., A novel function for galectin-1 at the crossroad of innate and adaptive immunity: Galectin-1 regulates monocyte/macrophage physiology through a nonapoptotic ERK-dependent pathway (2007) J Immunol, 178, pp. 436-445
• Riihijärvi, S., Fiskvik, I., Taskinen, M., Vajavaara, H., Tikkala, M., Yri, O., Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: A correlative study from a Nordic phase II trial (2015) Haematologica, 100, pp. 238-245

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------